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Abstract 
 Hyper IgE syndrome (HIES) is a multisystem disorder resulting in bone 
and immune system abnormalities. It is associated with mutations in STAT3, which 
disrupt protein domains responsible for transcriptional function. Patients with HIES 
display osteoporosis and enhanced inflammatory cytokine production similar to 
hematopoietic Stat3-deficient mice. Since osteoclast and inflammatory cytokine genes 
are NFκB targets, these observations indicate a possible deregulation of NFκB 
signaling in both mice and humans with STAT3-deficiency. Here, we sought to 
examine the role of STAT3 in the regulation of NFκB-mediated gene expression 
through analysis of three HIES STAT3 point mutations in both hematopoietic and non-
hematopoietic cells. We found that IL-6-induced tyrosine phosphorylation of STAT3 
was partially or completely abrogated by HIES mutations in the transactivation domain 
(V713L) or SH2 domain (V637M), respectively, in both hematopoietic and non-
hematopoietic cells. By contrast, IL-6-induced tyrosine phosphorylation of an HIES 
mutant in the STAT3 DNA-binding domain (R382W) was intact. The R382W and 
V713L mutants significantly reduced IL-6-dependent STAT3 transcriptional activity in 
reporter gene assays. Moreover, the R382W and V637M mutants significantly 
diminished IL-6-responsive expression of the endogenous STAT3 target gene, Socs3, 
as assessed by quantitative real-time PCR (qPCR) in the RAW macrophage cell line. 
These observations indicate the HIES mutants dominantly suppress the transcriptional 
activity of wild type STAT3, albeit to varying degrees. All three HIES mutants 
enhanced LPS-induced expression of the NFκB target genes IL6 (IL-6), Cxcl10 (IP-
10), and Tnf (TNFα) in RAW cells, as indicated by qPCR. Furthermore, overexpression 
of wild type STAT3 in Stat3-deficient murine embryonic fibroblasts significantly 
reduced LPS-stimulated expression of IL6, Cxcl10, and IL12p35. In addition, in a 
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primary murine osteoclast differentiation assay, a STAT3-specific SH2 domain inhibitor 
led to significantly increased levels of osteoclast-specific gene expression. These 
results suggest that STAT3 serves as a negative regulator of NFκB-mediated gene 
expression, and furthermore imply that STAT3 mutations associated with HIES 
contribute to the osteopenia and inflammation observed in HIES patients.	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Introduction 
 
Hematopoiesis: 
 The cellular components of the immune system are generated through the 
process of hematopoiesis or blood formation. This begins with the differentiation of 
pluripotent hematopoietic stem cells (HSCs) in the bone marrow to a multipotent 
progenitor (MPP) and eventually to the development of the various effector subsets of 
both innate and adaptive immunity (Figure 1a) [1]. The cells of the adaptive immune 
response, namely T- and B- lymphocytes, differentiate from the common lymphoid 
progenitor (CLP), whereas the generation of innate immune cells occurs primarily 
through a process known as myelopoiesis, beginning with the common myeloid 
progenitor (CMP). These cells include the granulocytes (neutrophils, basophils, and 
eosinophils), dendritic cells, and macrophages. They act to protect the body from 
infection through secretion of various inflammatory cytokines along with physically 
interacting with the pathogens to remove them from the system. Macrophages are a 
prime example of this. However, given the right cytokine milieu, macrophages can also 
continue to differentiate further into cells known as osteoclasts in a process termed 
osteoclastogenesis.  
 
Osteoclastogenesis: 
 The bone microenvironment is a highly dynamic system under the control of two 
main cell types: bone-producing osteoblasts and bone-resorbing osteoclasts. In 
normal individuals, there exists a unique balance between the functions of these two 
cell types to maintain a consistent bone density. However in individuals where one of 
these cell types is either over- or under-reactive, the pathologies of osteopetrosis  
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(bone hardening) or osteoporosis (reduced bone density) arise. The 
osteoclastogenesis pathway, beginning with the hematopoietic stem cells through the 
monocyte/macrophage lineage and eventually terminating in the production of bone-
resorbing osteoclasts, is under the control of multiple cytokine as well as transcription 
factor signals (Fig. 1b). The Receptor-activator of NFkB (RANK) pathway is essential 
for osteoclastogenesis and disruption of this pathway leads to severe osteopetrosis 
[2][3][4]. In vitro, osteoclasts are generated from bone marrow macrophages after 
addition of the soluble ligand for RANK, RANK ligand (RANKL), for 3-5 days and 
develop generally from fusion of multiple macrophages to form the multinucleated 
osteoclasts, which posses the ability to resorb bone [5][6].  
 RANK has been identified as a member of the tumor necrosis factor receptor 
(TNFR) super family [7].  In a ligand-dependent manner [8], after binding of RANKL, 
the receptor trimerizes, inducing recruitment of members of the TNFR-associated 
factor (TRAF) family, primarily TRAF6 although TRAFs 1, 2, 3, and 5 have been 
shown to bind RANK in vitro [9]. TRAF6 is an E3-ubiquitin ligase, and functions as 
such in concert with an E2-ubiquitin conjugating complex of Ubc13 and Uev1A [10]. 
Uev1A, an E1-ubiquitin ligase, activates the ubiquitin monomers and then 
subsequently transfers them transiently to Ubc13, an E1/E2-ubiquitin conjugating 
enzyme. Ubc13 then transfers the activated ubiquitin to TRAF6, which ligates it to its  
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target proteins [11]. Upon RANK activation, the TRAF6/Ubc13/Uev1A complex is 
recruited to a specific motif, on the cytoplasmic tail of RANK, which it binds with high 
affinity [12]. Through auto-ubiquitination of TRAF6 on a lysine residue at position 63, 
known as K63-linked polyubiquitination, Tak1-binding protein 2 (TAB2) can bind 
TRAF6. TAB2 then acts as a scaffold to allow binding of the TGFβ-activating kinase 1 
(TAK1)/Tak1-binding protein 1 (TAB1) complex [13]. This association of TAK1/TAB1 
with TRAF6 allows TRAF6 to ubiquitinate TAK1, thus activating it [14]. This complex 
goes on to activate both the MAPK and the NFkB signaling pathways via 
phosphorylation cascades resulting in activation of AP-1 and Nuclear Factor-kappa B 
(NFκB), respectively (Figure 2).  
 Activation of the RANK signaling pathways in osteoclast precursors eventually 
leads to the terminal differentiation of multinucleated osteoclasts capable of resorbing 
bone matrix. These osteoclasts have multiple phenotypic markers that serve as 
identifiers of the stage of osteoclast differentiation. As the osteoclast precursors begin 
to fuse, they up-regulate Tartrate-resistant acid phosphatase (TRAP) and Calcitonin 
receptor (CALC) on the cell surface [15]. Cathepsin K (CSK), a cysteine protease, is 
also up-regulated at this point and primarily functions in the resorptive process [16]. 
 
NFκB-mediated inflammation: 
 While the TRAP, CALC and CSK osteoclast-specific markers have not been 
determined to be direct targets of NFκB, it is clear that NFκB is an important modulator 
of osteoclast differentiation [17][18]. NFκB  also functions in the innate immune 
system. One of its main roles is in production of pro-inflammatory mediators 
[19][20][21] via pathways that have been activated by pathogens recognized via a sect 
of innate immune receptors knowns as Toll-like receptors (TLRs), including TLR4  
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[22][23][24]. This inflammatory response is especially important for macrophages, as 
they are a primary effector of the innate immune system and one of the first defenses 
against infection [25].  
Inflammatory signaling in macrophages occurs through various receptors both 
on the cell surface and in the cytosol. Macrophages highly express a variety of TLR, 
which recognize conserved pathogen-associated molecular patterns (PAMPs). These 
PAMPs are conserved motifs commonly found on different types of pathogens, 
including bacteria, fungi, and viruses. For example, TLR2 recognizes peptidoglycan, 
TLR7 recognizes single-stranded RNA, and TLR4 recognizes lipopolysaccharide 
(LPS) [22].  The effector products of each of the TLRs vary. Activation of TLR4, for 
example, induces activation of the NFkB and MAPK signaling cascades resulting in 
the production of a variety of inflammatory gene products [23][24][26]. 
 Binding of LPS to TLR4 results in the dimerization of the receptors, and binding 
of the intracellular adaptor proteins TIR-domain-containing adapter-inducing interferon-
β (TRIF) or myeloid differentiation primary response gene (MyD88) [27]. This elicits the 
binding and activation of IL1-receptor associated kinases 1, 2, and 4 (IRAK1/2/4) 
[28][29]. These adaptor molecules then recruit the E3-ubiquitin ligase TRAF6, similar 
to the RANK pathway. Polyubiquitinated TRAF6 then activates the NFkB and MAPK 
pathways as discussed previously, leading to expression of inflammatory cytokines 
including but not limited to tumor necrosis factor alpha (TNFα), Interleukin-6 (IL-6), IL-
12, Interferon-gamma induced protein 10 (IP-10; Cxcl10), and IL1-β (Figure 3) 
[30][31][32][33]. Interestingly, LPS has also been shown to induce osteoclastogenesis 
from bone marrow precursors as one might expect from the similarity of the TLR4 and 
RANK signaling pathways [34][35].  
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Another pathway highly important in myeloid cell development, function and 
inflammation is the JAK-STAT pathway [36-38]. Binding of a cytokine ligand to its 
cognate trans-membrane receptor primarily activates this pathway. The signal-
transducer and activator of transcription (STAT) proteins have been shown to be 
important for myeloid cell development, homeostasis and function including 
inflammatory gene expression as discussed below [39-43].   
 
The JAK/STAT pathway: 
 The STAT family of proteins consists of 7 members: STAT1, 2, 3, 5a, 5b, and 6 
[44]. STATs can form homo- or hetero-dimers in the cytoplasm upon specific 
stimulation of growth factor or cytokine receptors on the cell surface. Once activated, 
the STATs function as transcription factors to regulate cell growth, differentiation, 
survival, and function [45]. Figure 4 depicts a more detailed look at how the cytokines 
transduce a STAT-dependent signal to the nucleus to stimulate gene transcription. 
After binding of the cytokine or growth factor ligand to the receptor, the monomers 
dimerize bringing the receptor-associated kinases on the cytoplasmic tails together 
[46][47]. This allows cross-phosphorylation of the kinases as well as the receptor 
cytoplasmic tails at specific tyrosine residues [47]. These phosphorylated residues 
create docking sites for the STAT proteins to bind via their Src-Homology 2 (SH2) 
domains [48]. The receptor-associated kinases then phosphorylate the STAT proteins 
on a specific tyrosine residue (Y705 for STAT3), allowing the STAT monomers to 
associate into dimers via SH2-phosphotyrosine-interactions [49][44]. These activated 
STAT dimers now translocate to the nucleus where they can function as transcription 
factors. This pathway has been termed the canonical pathway of STAT signaling [50].  
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As was stated earlier, STATs function broadly in immune cell function, 
differentiation, and maintenance. The physiological role of each STAT family member 
has been widely studied through the use of both complete and conditional knockout 
mice [51]. While each is important in its own right, STAT3 has been the only STAT to 
show early embryonic lethality [52] which indicates its importance for cell growth, 
differentiation, and function early in the developmental process [53]. 
  
STAT3: 
 STAT3 has a structure like other STAT proteins (Figure 5). It contains an N-
terminal region, followed by a coiled-coiled domain, and a DNA-binding domain 
[54][53] The C-terminal region contains the SH2-domain and finally a transactivation 
domain (TAD) [53]. The important tyrosine residue is located in the SH2 domain 
adjacent to the TAD. A serine residue that also undergoes phosphorylation most likely 
via serine/threonine kinases is located in the TAD at position 727. Phosphorylation at 
this serine residue has been shown to enhance STAT3 mediated transcription [55] but 
is unnecessary for STAT3 DNA binding [56]. 
Signaling via STAT3 can occur similarly to other STAT proteins, via the 
canonical pathway (Figure 4). In the IL-6 response, STAT3 activation involves both the 
IL-6-receptor alpha chain (IL-6Rα), which binds IL-6, followed by the binding of IL-6/IL-
6Rα to the signaling subunit, gp130 [57]. Additional cytokines that activate STAT3 via 
gp130 include: IL-10, IL-11, IL-21, IL-23, Leukemia Inhibitory Factor (LIF), and 
Oncostatin M (OSM). Granulocyte-colony stimulation factor (G-CSF) and Interferon-
alpha/beta (IFN-α/β) also activate STAT3 although not through gp130-mediated 
signaling [58][59][60].  
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Recently, two groups identified two non-canonical STAT pathways. In 
Drosophila melanogaster, it has been shown that the single STAT protein, STAT92E, 
while unphosphorylated, can mediate heterochromatin structure and stability via its 
association with heterochromatin protein 1 (HP-1) [61]. Subsequently, it was shown 
that STAT3, phosphorylated solely on the serine residue at position 727, could 
regulate cellular respiration in mitochondria via interactions with electron transport 
chain complexes I and II [62] and this function comes at the expense of its canonical 
transcriptional function. These discoveries are in stark contrast to the traditional view 
of STATs as transcription factors. While the Drosophila STAT protein is more closely 
related to STAT5, it has yet to be shown whether any of the other STATs have a 
similar function in Drosophila or in mammals.  
It would seem however that the canonical view of STAT3 might not be the only 
function this particular protein has in the cell. In support of this idea, unphosphorylated 
STAT3 has a transcriptional function as well and upregulates a number of oncogenes 
found in various types of cancer [63]. A function for STAT4 and STAT6 was also 
identified in regulating chromatin activation status through regulation of epigenetic 
activation and repression marks [64]. STAT4 was shown to increase the histone 3 
lysine 4 trimethylation (H3K4me3), known to be an activating marker; STAT6 on the 
other hand decreased the amount of H3K27me3, a known repression marker. Another 
member of the JAK/STAT pathway, namely JAK2, has also recently been identified to 
have a role in regulating heterochromatin structure through inhibiting the binding of 
heterochromatin protein 1-α (HP1-α) by phosphorylating tyrosine 41 (T41) on histone 
H3 (H3) leading to a more open and active chromatin conformation [65]. 
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STAT3 and inflammation: 
 Due to the inability to generate genome-wide STAT3 knockout mice because of 
the embryonic lethality [52], it is necessary to study STAT3’s function in a lineage-
specific context. Hematopoietic STAT3-deficient mice have been produced [43]. These 
mice display mild to moderate osteoporosis [66] as well as a Crohn’s disease-like 
phenotype characterized by increased infiltration of myeloid cells most likely 
responsible for the observed increase in production of inflammatory cytokines and 
severe deterioration of the bowel and intestinal tract [43][67].   
STAT3 is important for both positively and negatively regulating inflammation. 
This is evidenced not only through its known activation by IL-6 [57], an inflammatory 
cytokine, but also through the dependence of inflammatory IL-17-producing helper T 
cells (TH17) on STAT3’s regulation of retinoic acid receptor-related orphan receptor-γ-
T (RORγT), a TH17-lineage specific transcription factor [68]. STAT3’s anti-
inflammatory role has also been well characterized. Evidence suggests this occurs 
primarily through IL-10, a known anti-inflammatory cytokine, whose expression is 
dependent on STAT3 in both mice and humans [69][70]. IL-10 also signals through 
STAT3 to inhibit the proliferation of macrophages [71]. STAT3 auto-regulates 
inflammatory cytokine signaling via induction of suppressor of cytokine signaling 3 
(SOCS3), which competes with STAT3 for binding to the cytoplasmic portion of the 
receptor thus attenuating signaling [72]. Inflammation has not only been shown to be 
important in the immune system setting, but through epidemiological studies, it is 
evident that inflammation is a key player in oncogenesis [73][74]. 
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STAT3 and cancer: 
The link between inflammation and cancer development is an intense area of 
study because of the implication that targeting the immune system may lead to more 
effective cancer treatment and prevention [60][75]. As was noted earlier, STAT3 is an 
important regulator of inflammation and cellular growth control, and thus has been a 
focus for its role in promoting tumorigenesis. STAT3 signaling is commonly overactive 
in solid tumors [76][77]. The relationship between the tumor cells and tumor-
associated non-transformed cells is important for cancer progression and cell survival 
possibly due to a STAT3 feed-forward loop [59]. STAT3 along with NFκB are important 
mediators of cancer-associated inflammation [73] and persistent activation of STAT3 
in immune cells leads to defective immune responses against the tumor [60].  
These two molecules are important not only for the growth and survival of 
tumors, but also function to stimulate the epithelial-mesenchymal transition of tumors, 
which is the first step in their metastasis to other organs [78-80]. The effectors of this 
transition can be inflammatory cytokines such as IL-6, IL-1, TNFα, and transforming 
growth factor-β (TGFβ) [78] leading to expression of NFκB and STAT3 targets 
important for this transition [79][80]. 
STAT3 seems to have a dual role in inflammation and cancer. In non-immune 
cells, STAT3 functions to promote cell survival and proliferation [81]. In tumor-
associated immune cells, unphosphorylated STAT3 interacts with NFκB to produce 
inflammatory signals that aid the cancer cells in survival and eventual metastasis 
[82][83]. Moreover, in myeloid cells, STAT3 regulates cell survival, growth and function 
[36][42], but also is responsible for anti-inflammatory responses via inducing IL-10 
expression and participating in IL-10 signaling, including suppression of TLR4-induced 
inflammatory gene expression [38][69][70][71]. 
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 The immunosuppressive functions of STAT3 signaling via IL-10 have been well 
characterized, as has its function in promoting oncogenesis through its pro-
inflammatory interactions with NFκB. Recently, STAT3 has been implicated as the 
effector of another human syndrome whose phenotype encompasses each of the 
known functions for STAT3 both in inflammation and cancer. 
 
Hyper-IgE Syndrome:  
 Hyper-Immunoglobin E (IgE) syndrome (HIES), otherwise known as “Job’s 
Syndrome” due to the skin lesions reminiscent of the lesions of Job in the Bible’s Old 
Testament, is a primary immunodeficiency with both an autosomal dominant (AD) or 
autosomal recessive (AR) heritability pattern. The characteristic phenotype of this 
disease includes elevated levels of IgE in the serum, skin lesions, cold abscesses, 
recurrent staphylococcal infections of the skin and respiratory tract, as well as bone 
abnormalities affecting the spine, teeth, and long bones, specifically osteopenia (Table 
1, & [84]). Several types of cancer have also been correlated with this disease 
[85][86][87]. Until recently, the genetic cause for this disease was unknown.  
 In 2007, two groups concordantly discovered the genetic basis for this disease. 
Multiple individual mutations in the STAT3 gene were identified in individuals 
presenting with the AD form of HIES ([88][89]. The authors noted that the mutations 
occurred primarily in the DNA-binding domain, SH2-domain, and the TAD, and most 
likely affected the protein structure such that the mutant STAT3 proteins acted like 
dominant negatives by interfering with the wild-type STAT3 and preventing its 
activation or its ability to bind DNA. Since then, a fair amount of research has been 
focused on determining how STAT3 induces the phenotypic abnormalities associated 
with HIES.  
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Table 1. Phenotype of STAT3 deficient mice and 
humans with HIES  
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`  Possibly the most devastating pathology of this disease is the recurrent 
infections in the majority of patients. These can range from infections caused by the 
Staphylococcus and Streptococcus families [90] to the Pseudomonas and Aspergillus 
families. In most cases, these infections have been deemed the cause of death [91]. 
Therefore, most research to date has been focused on how the loss of STAT3 impairs 
the immune system in such a way as to allow these microbes to proliferate unchecked. 
Several groups have made key observations in this respect. 
 Patients with HIES have an observed lack of Th17 cells both in vitro and in vivo 
[92][93][94]. Given STAT3’s importance for the expression of retinoid–related orphan 
receptor γT (RORγT) [68], the loss of Th17 cells, which depends on RORγT for their 
development, makes sense. This severe lack of Th17 could play a large part in the 
susceptibility to fungal and bacterial pathogens found often in patients with HIES. 
Further evidence suggests that STAT3’s function in IL-10 signaling may also be 
important for the imbalanced inflammatory response in patients with HIES. While 
lymphocyte numbers in the blood remain normal, dendritic cells (DC) were found to be 
unable to become tolerogenic in the presence of IL-10, as well as to induce naïve 
CD4+ T cells to becoming inducible T-regulatory cells (iTregs) [95]. DC from HIES 
patients were also shown to secrete more inflammatory cytokines, even in the 
presence of IL-10 [96]. 
 By comparing what is known about patients with HIES and mice with 
hematopoietic specific deletion of Stat3, it is reasonable to propose that STAT3 is 
important for regulating bone development, immunity against bacterial and fungal 
pathogens, and production of NFκB-regulated inflammatory cytokines. However, no 
direct evidence to date suggests how STAT3 is affecting bone development and 
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homeostasis, or how STAT3 is affecting NFκB-mediated inflammatory gene 
expression in these two models. 
 
Project Goal: 
 Traditionally, STAT3 has been considered to solely act as a transcription factor 
in the regulation of pathways leading to cell growth, survival, and differentiation as well 
as in regulation of inflammation. Although STAT3 has been shown to be important in 
bone development [66], little data exists elucidating the exact mechanism as to how it 
is involved. Data from our lab and others (H. Zhang, unpublished data)[82][97] 
indicates a role for STAT3 in regulating NFkB signaling in the hematopoietic system. 
The goal of this project was to examine how the point mutations identified in HIES 
affect STAT3’s function in NFkB-mediated gene expression and by doing so, gain a 
more detailed understanding of the role for each domain in this regulation.  
 
Methods 
Cell Lines, Culture Conditions and Cytokine/LPS Treaments: 
 
Primary murine macrophages were generated from total bone marrow, collected from 
6-8 week old C57BL/6 mice, by culturing in DMEM containing 20% fetal calf serum 
(FCS) and 20% conditioned medium from L929 cell supernatants (source of M-CSF) 
for 3 days. Primary murine osteoclasts were then generated by addition of 50ng/mL 
RANKL (R&D Systems, #390-TN-010) for 4 days. RAW cells (mouse macrophage cell 
line) were cultured in DMEM supplemented with 10% FCS. Similarly, the STAT3-null 
murine embryonic fibroblast cell line (L1) was maintained in DMEM with 10% FCS. 
The RAW and L1 cells expressing WT STAT3 or one of the STAT3 point mutations 
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were generated by retroviral transduction. Briefly, 3x105 cells were plated in a 6-well 
plate and allowed to adhere for 30 minutes at 37° C. 1 mL of retrovirus was then 
added to 0.5 mL complete media along with 8ug/mL polybrene. Cells were spun at 
2300 rpm for 1 hour, then allowed to incubate for 4 hours before media was aspirated 
and replaced with DMEM plus 10% FCS. Cells were subject to sorting for GFP+ cells 
after 48 hours. For assays involving analysis of STAT3 transcriptional activity, cells 
were treated with murine IL-6 (25ng/mL: R&D systems #406-ML-005) or mIL-6 plus 
mouse soluble IL-6 receptor alpha (sIL-6Rα) (25ng/mL:  R&D systems #1830-SR-025) 
for 30 minutes (immunoblots), 3 hours (luciferase assays), or indicated time points 
(quantitative real-time PCR).For primary osteoclast differentiation assay and STAT3 
inhibitor quality control, cells were stimulated with 20 ng/mL recombinant human G-
CSF. For inflammatory gene expression analysis, 1x106 RAW cells were plated in a 12 
well plate in 1mL media and starved overnight in DMEM with 1% FCS. RAW cells 
were then stimulated with Lipopolysaccharide (LPS) (100ng/mL: Sigma #L3024) for 
the indicated time points. 5x105 L1 cells were plated in a 6 well dish and starved 
overnight in DMEM with 1% FCS. L1 cells were then stimulated with LPS (100 ng/mL) 
for indicated time points. All cells were maintained in a humidified incubator at 37° C 
and 5% CO2.  
STAT3 mutant generation: 
STAT3 cDNAs encoding individual point mutations (R382W, V637M, and V713L) were 
generated by Dr. Huiyuan Zhang using the QuikChange II Site-Directed Mutagenesis 
kit (Stratagene, #200523) as described in the manufacturers protocol. The presence of 
the mutations was confirmed by DNA sequencing. The truncated STAT3 mutants were 
generated (TAD: X. Xie and Watowich unpublished results, Δ133: L. Zhang [100]) 
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using a PCR-based strategy and confirmed by gel electrophoresis and DNA 
sequencing.  
Production of VSVg-pseudotyped MCSV-based STAT3 retroviruses: 
cDNAs encoding WT STAT3 or the three HIES point mutants described previously 
were cloned into the pMX-IRES-GFP retroviral vectors via digestion with Sph1 and 
Not1 and confirmed by gel electrophoresis. Retroviruses were then generated using 
the 293T packaging cell line via the calcium-phosphate transfection method. Briefly, 
14ug plasmid cDNA along with cDNA encoding the packaging constructs (8ug VSVg, 
10ug Gag/Pol) were mixed with CaCl2 and water. Hepes-buffered saline (HBS) was 
then added drop by drop to the DNA/CaCl2 mixture while bubbling. This mix was then 
allowed to sit for 5 minutes before adding drop-wise to the plate of 293T cells (60-80% 
confluency) in DMEM with 10% FCS and 20uM chloroquine. Cells were incubated for 
8 hours and then medium was replaced with fresh DMEM plus 10% FCS. Supernatant 
containing viral particles was collected after 48 and 72 hours and used fresh or frozen 
(stored at -80°C). 
STAT3 SH2 domain inhibitor: 
A STAT3-specific SH2 domain inhibitor (73g) was kindly provided by Dr. John 
McMurray (M.D. Anderson Cancer Center). The unreconstituted inhibitor was stored at      
-20° C. For working concentrations, inhibitor was reconstituted in 99.9% pure DMSO at 
and aliquots were frozen at -80° C. For STAT3 inhibition experiments, the inhibitor was 
added at the indicated concentrations and replaced every 12 hours for the indicated 
time period.  
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Preparation of whole cell lysates, SDS-polyacrylamide gel electrophoresis, and 
immunoblot analysis: 
Cells were treated as indicated (section: Cell Lines, Culture Conditions and 
Cytokine/LPS Treaments) and then washed with 1X PBS. Laemmli gel sample buffer 
(2% SDS, 80mM Tris pH 6.8, 15% Glycerol, 0 v.01% Bromophenol Blue, 1% 
Betamercaptoethanol) was added and the cell pellet was sonicated and boiled (10 
minutes, 100°C) for whole cell lysates. 5x105 (Raw)/2.5x105 (L1) cell equivalents were 
separated on 10-15% SDS-polyacrylamide gels by electrophoresis. Protein was then 
electrophoretically transferred to a nitrocellulose membrane for antibody staining. 
Membranes were briefly washed in ddH20 and then blocked for 1 hour at room 
temperature. For phosphorylated STAT3, 5% BSA in TBST (1X TBS, 0.05% Tween-
20) was used for blocking. For total STAT3 and RAN, 5% milk in PBST (1X PBS, 
0.05% Tween-20) was used. For total and phosphorylated JNK, 5% milk in TBST was 
used for blocking. For Tubulin, 1% BSA in TBST was used for blocking. Membranes 
were then incubated overnight at 4° C with primary antibodies in their respective 
diluents: Phosphorylated STAT3 (1:1000 in 5% BSA-TBST, Cell Signaling #9131S ), 
STAT3 (C-20/H-190, 1:1000 in 5% milk-PBST, Santa Cruz Biotechnologies, #SC-482 
& SC-7179), Phosphorylated JNK (1:500 in 5% BSA-TBST), total JNK1 (1:500 in 5% 
milk in PBST), Tubulin (1:1000 in 1% BSA-TBST, Sigma #T9026), Ran (1:1000 in 5% 
milk-PBST, Santa Cruz Biotechnology, #SC-1156). After overnight incubation, 
membranes were washed with PBST three times followed by addition of secondary 
antibody for incubation at room temperature for 2 hours (pSTAT3/STAT3/pJNK, anti-
rabbit IgG-HRP, GE-life sciences #NA934; Tubulin/JNK1, anti-mouse IgG-HRP, GE-
life sciences #NA9310; and for Ran, anti-goat IgG-HRP, Santa Cruz #SC-2020, were 
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used). Membranes were washed 3 more times in PBST followed by development 
using West Pico Substrate (Thermo Scientific, #34087). 
Quantitative Real-time polymerase chain reaction (qPCR): 
Cells were treated as indicated and then lysed in Trizol Reagent (Molecular Research 
Center, #TR118). Total RNA was extracted per the manufacturer’s protocol and RNA 
concentration was analyzed on a Nanodrop-1000. 1ug of total RNA was subjected to 
reverse transcriptase PCR (RT-PCR) using the IScript system (Biorad, #1708891). 
cDNA was diluted 1:5 and 5uL was used for each sample in qPCR. Samples were 
combined in a 20uL mixture containing nuclease-free water, specific oligonucleotides, 
and iQ SYBR Green mastermix (Biorad, #1708882). Each sample was run in duplicate 
on a Biorad C1000 Thermal Cycler CFX96 Real-time system. PCR conditions were: 
95°C 3 min, (95°C 10 seconds, 59°C 20 seconds, 72°C 30 seconds) X 39 cycles. 
Samples calculations were relative to an internal control, 18s rRNA. Data were 
analyzed using the ΔΔCt method in Microsoft Xcel using the formula [Relative 
expression level=power(1.8, (Control Ct value – Target Ct value))*107]. P values were 
calculated using either Student’s t-test or 2-way ANOVA with a Bonferroni post-test.  
Oligonucleotide sequences for qPCR:  
Please see Table 2 
Transient Transfection for STAT3 overexpression: 
293T cells were grown to 60-80% confluency prior to transfection. 10ug of DNA was 
transiently transfected using the calcium phosphate method described in section: 
Production of VSVg-pseudotyped MCSV-based STAT3 retroviruses. Cells were 
incubated with DNA precipitate and 20uM chloroquine in DMEM plus 10% FCS for 6 
hours and then the media was replaced. Cells were then incubated for 48 hours before 
analysis by immunoprecipitation and immunoblotting.  
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Flag-immunoprecipitation and immunoblotting: 
10-20x106 cells were pelleted and washed with 1X PBS containing a protease inhibitor 
cocktail (Roche, #11873580001) and placed on ice. Pellets were lysed in 0.5mL non- 
denaturing isotonic triton lysis buffer (1% Triton X-100, 50mM Tris-Cl ph 7.4, 300mM 
NaCl, 5mM EDTA, 0.02% Sodium Azide) containing the protease inhibitor cocktail 
(Roche) on ice for 5 minutes. Lysates were spun at 14,000 RPM at 4° C for 15 
minutes. Supernatants were collected and 20uL Protein-G agarose beads (Santa Cruz 
Biotechnology, #SC-2002) was added to pre-clear lysate of non-specifically bound 
proteins. Samples were rotated at 4° C for 1 hour. Samples were then spin to remove 
cell debris and supernatants were collected. Protein concentration was detected and 
normalized between samples. One-tenth of the total volume was removed to use for 
the input controls. 2uL of anti-Flag M2 antibody (Sigma, #F3165) were then added and 
samples were rotated overnight at 4° C. Then Protein-G agarose beads (40uL) were 
added and samples continued to rotate at 4° C for 1 hour. Samples were spun and 
supernatants were discarded. Beads were washed 3X with isotonic Triton lysis buffer 
containing protease inhibitor and 1X with PBS containing protease inhibitor and then 
resuspended in 40uL Lammeli sample buffer and boiled for 10 minutes. 40uL 
immunoprecipitated and input samples were run on a 15% polyacrylamide gel and 
electrophoretically separated and STAT3 expression was analyzed by immunoblot.  
Transfection of STAT3-deficient mouse embryonic fibroblasts for Luciferase assay 
1x104 STAT3-/- MEFs were plated in duplicate per well of a 48 well plate in 0.2 mL 
complete DMEM the night before transfection. On the following day, cells were 
transfected using Lipofectamine LTX and PLUS reagent (Invitrogen #15338030) 
according to the manufacturers protocol. Briefly, 0.4ug of total DNA was diluted in 40 
uL serum free media per well. PLUS reagent (0.4uL) was added to the diluted DNA 
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and incubated at room temperature for 15 minutes. Lipofectamine LTX was added 
(0.2uL) to DNA:PLUS mixture, and incubated for 30 minutes at room temperature. 
Finally, 40 uL/sample was added to each well of the 48-well plate and incubated for 
40-48 hours. The ratio of DNA to lipid was optimized according to the manufacturers 
optimization protocol.  
Luciferase assays 
Transfected STAT3-deficient mouse embryonic fibroblasts were assayed for luciferase 
activity using the Promega Dual-luciferase reporter kit following an amended 
manufacturers protocol. After a 3 hour stimulation with 25ng/mL IL-6 and 25ng/mL sIL-
6Rα, cells in a 48-well plate were lysed with passive lysis buffer for 15 minutes at room 
temperature. 5 uL lysate per sample was mixed with 5uL luciferase assay reagent II 
and then the firefly luciferase was read using a Sirius Luminometer from Burthold 
Detection systems. Stop and Glo reagent was added (5uL) and the background renilla 
luciferase activity was detected. Each sample was transfected in duplicate, and then 
averaged before being normalized to the average renilla luciferase reading.  
 
Results: 
Generation of the STAT3 mutant constructs 
  STAT3 contains 5 distinct protein domains: N-terminal region, coiled-coiled 
domain, DNA-binding domain, SH2-domain and C-terminal transactivation domain 
(TAD). Traditionally the DNA-binding region, SH2 domain, and TAD are considered to 
be important for STAT3’s function as a transcription factor, whereas the others may be 
involved in protein-protein interactions [53].  
 To evaluate how STAT3 functions in osteoclastogenesis and inflammatory gene 
expression, we first generated STAT3 constructs containing mutations in each of these 
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domains (Fig. 6). Previous members of our lab generated an N-terminal truncated form 
of STAT3, termed Δ133 for the loss of the first 133 amino acid residues [100], as well 
as a construct that lacks the entire transactivation domain at the C-terminus [X. Xie 
and S. Watowich, unpublished results]. These were generated via a polymerase chain 
reaction (PCR)-based strategy. A published construct, EE/VVV, was provided by Drs. 
Curt Horvath and Jim Darnell, and has been shown to elicit dominant negative activity 
[54]. Finally, we chose three of the published point mutations identified in patients with 
HIES (R382W, V637M, and V713L) and generated them via site-directed mutagenesis 
[H. Zhang and S. Watowich, unpublished results]. R382W is located within the DNA-
binding domain and is predicted to function similarly to the EE/VVV mutant by allowing 
STAT3 phosphorylation and dimerization but preventing its binding to promoter 
elements on the DNA. V637M is located within the SH2-domain, and published reports 
show that it lacks the ability to become tyrosine phosphorylated after EGF stimulation 
of transiently transfected COS-7 cells [98]. V713L is found in the transactivation 
domain but adjacent to the SH2 domain in tertiary protein structures as seen through 
virtual protein modeling [E. Ohashi and S. Watowich, unpublished results]. While there 
are no reports on how this mutation affects STAT3 signaling, we hypothesize that it will 
act similarly to the V637M mutation due to its proximity to the SH2 domain and the 
important tyrosine residue at position 705.  
To confirm that these constructs were expressed in vitro, we transiently 
transfected 293T cells with plasmids encoding each mutant, all containing in-frame C-
terminal FLAG epitope tags, and evaluated their expression by immunoprecipitation 
with anti-FLAG antibodies and immunoblotting for total STAT3. We found that each 
construct was expressed at relatively similar levels, excluding the EE/VVV and TAD 
mutants (Fig. 7). Each mutant construct was expressed from a green fluorescent  
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protein (GFP)-containing vector to assist us in tracking the expression of mutant 
proteins throughout our experiments. Prior to each experiment, the GFP expression 
was checked via fluorescent microscopy and multiple times throughout the project a 
confirmatory immunoblot was run to verify continued expression of the mutants. Based 
on this result, we chose to focus on comparing wild-type (WT) STAT3 with the three 
HIES point mutations in our studies.  
 
Effects of HIES mutants upon phosphorylation of endogenous STAT3 
 The STAT3 mutations identified in patients with HIES have been assumed to be 
dominant negative due in part to the heterozygosity of HIES patients as well as in vitro 
assays performed with mutated STAT3 isoforms in cell culture systems [88]. The 
dominant negative action of mutated STAT3 in HIES is proposed to lead to the severe 
clinical defects with this syndrome including osteopenia, increased incidence of 
infection, and high IgE serum levels. However, of the three mutations we were 
interested in, only the mutation located in the DNA-binding domain (R382W) has been 
assayed for dominant negative activity via luciferase assays [88][89]. We wanted to 
determine whether the other mutations, V637M and V713L, also elicited dominant 
negative inhibition of STAT3 function. 
 We initially utilized retroviral transduction to express each mutant in a murine 
macrophage cell line (RAW cells). To confirm the expression of the mutants in our 
system, we performed immunoprecipitation and immunoblotting assays with FLAG and 
STAT3 antibodies, respectively. We found that each mutant was expressed at equal 
amounts (Fig. 8).  
 To determine if the mutants affect activation of endogenous STAT3, we 
stimulated RAW cells expressing each mutant with soluble IL-6 (sIL-6) for 30 minutes  
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and then examined STAT3 tyrosine phosphorylation by immunoblotting. We found 
total STAT3 tyrosine phosphorylation amounts were similar or slightly higher in cells 
expressing the R382W mutant (mutated in the DNA-binding domain), compared to 
cells with WT STAT3 overexpression (Fig. 9a). By contrast, overexpression of the 
V637M mutation significantly diminished the level of STAT3 tyrosine phosphorylation 
compared to WT STAT3. The level of this tyrosine phosphorylation was similar to the 
level of tyrosine phosphorylation observed in uninfected RAW cells stimulated with sIL-
6 (Fig. 9b). Importantly, cells expressing the V713L mutation, which is located in the 
TAD but adjacent to the SH2 domain, showed a slightly increased amount of total 
STAT3 tyrosine phosphorylation compared to uninfected macrophages, while 
exhibiting significantly less compared to cells overexpressing WT STAT3 (Fig. 9a). 
Together these data suggest that the mutations in the SH2 domain and TAD affect 
STAT3 tyrosine phosphorylation, whereas mutations in the DNA-binding domain do 
not. 
 
Activation of STAT3 HIES mutants 
 Due to our data examining total STAT3 tyrosine phosphorylation when 
overexpressing the HIES mutants, we intended to identify whether the mutants alone 
could become activated via IL-6 stimulation. Previous studies have shown that in 
transiently transfected COS-7 cells, epidermal growth factor (EGF) stimulation induced 
STAT3 tyrosine phosphorylation in cells transiently transfected with both WT STAT3 
and the R382W mutant STAT3, but not in cells expressing the V637M mutant [98]. We 
sought to confirm this observation within cells stably expressing the STAT3 HIES 
mutants in the absence of endogenous or overexpressed WT STAT3, under IL-6  
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stimulation conditions, as well as shedding light on the activation ability of the V713L 
mutant, which has not been tested to date.  
 Using STAT3-deficient MEFs, we stably reconstituted each STAT3 HIES 
mutant. To confirm that the mutants were expressed, and that the parental cells were 
truly STAT3-deficient, we examined total STAT3 protein expression by 
immunoblotting. Uninfected cells and cells infected with a GFP-containing empty 
vector (referred to as GFP-empty vector henceforth) were used as negative controls, 
while 293T cells were used as a positive control (Fig. 10). We found that the HIES 
mutants showed similar expression levels. The uninfected and GFP-empty infected 
cells confirmed a lack of STAT3 expression in STAT3-deficient MEFs. By contrast, the 
TAD, Δ133, and EE/VVV mutants were expressed at significantly lower amounts 
versus the HIES point mutants.  
 To examine directly the phosphorylation potential of the STAT3 HIES mutants, 
we used a combination of sIL-6 and soluble IL-6 receptor-α (sIL-6Rα; STAT3-deficient 
MEFs do not express IL-6Rα) to stimulate reconstituted STAT3-deficient MEFs for 30 
minutes and then assayed for STAT3 tyrosine phosphorylation by immunoblotting (Fig. 
11). Consistent with our data from the RAW cells, we found increased tyrosine 
phosphorylation in cells expressing the R382W mutant compared to cells expressing 
WT STAT3. We also confirmed previous reports showing the complete lack of tyrosine 
phosphorylation of the V637M mutant [98]. Interestingly, we found that the V713L 
mutant was phosphorylated following IL-6 stimulation; however, this appeared to occur 
less efficiently than the WT and R382W mutants when total STAT3 level was taken 
into account. Together these data indicate that the mutation in the DNA-binding 
domain does not inhibit tyrosine phosphorylation of STAT3 but rather enhances it (Fig. 
9 & 11). The SH2-domain mutation completely abrogates phosphorylation of this  
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mutant, and the TAD mutation allows STAT3 to be phosphorylated albeit at a much 
lower level compared to WT. 
 
Transcriptional activity of STAT3 HIES mutants 
 Next, we sought to identify whether the STAT3 HIES mutants were able to 
exhibit transcriptional activity. The suppressors of cytokine signaling (SOCS) proteins 
are competitive inhibitors of JAK/STAT signaling, which act via competition for binding 
to the tyrosine residues of gp130 [99]. The Socs3 promoter has been shown to contain 
a STAT3 binding site [100][101] and it is induced by STAT3 activation whereby 
SOCS3 potently inhibits further STAT3 activation after cytokine stimulation [101][102].  
 To analyze the transcriptional activity of the HIES mutants after IL-6 stimulation, 
we treated STAT3-deficient MEFs, reconstituted with the mutants, with sIL-6 and sIL-
6Rα. We then analyzed Socs3 mRNA expression at different time points by qPCR. 
Socs3 mRNA expression peaked at 30 minutes of IL-6/sIL-6Rα treatment (Fig. 12a) 
and was induced up to 40 fold (Fig. 12b) in WT cells. Figure 12a depicts the 
expression level of Socs3 RNA relative to an internal control gene. Figure 12b depicts 
the fold change of Socs3 RNA relative to the unstimulated control. In contrast, IL-6-
responsive Socs3 expression was significantly reduced in cells expressing the HIES 
mutants (p<0.001) compared to WT STAT3, with cells expressing the R382W and 
V637M mutants displaying no Socs3 induction compared to unstimulated samples 
(p<0.001). The V713L mutant elicited expression of Socs3, which was increased by 10 
fold in comparison to the R382W and V637M mutants (p<.001). However, this 
induction was still much diminished in comparison to Socs3 expression in WT STAT3 
cells. The Socs3 expression kinetics with the V713L mutant mirrored the expression 
pattern of Socs3 in WT STAT3 cells, with peak expression at 60 minutes post- 
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stimulation. These data indicate that the DNA-binding and SH2-domain mutations 
completely abolished STAT3’s transcriptional ability, whereas the V713L mutation did 
not. However, the level of transcriptional activity of the V713L mutant was significantly 
lower level than the WT cells. This correlates well with the partially decreased 
phosphorylation of the V713L mutant seen in both RAW and STAT3-deficient MEFs 
(Figs. 9 and 11). 
 
Dominant negative effects of STAT3 HIES mutants 
 While it is clear that each HIES mutation we tested severely diminishes the 
intrinsic transcriptional ability of the mutants of STAT3 (Fig. 12), it remained to be 
determined whether these mutations interfere with the transcriptional function of WT 
STAT3 thereby exhibiting proposed dominant negative activity. It has been shown that 
the R382W mutant does decrease STAT3 gene reporter activity in transiently 
transfected HepG2 cells after IL-6 stimulation [88]. Therefore we intended to confirm 
the dominant negative activity of this mutation and examine the activity of the V637M 
and V713L mutations as well.  
 Using STAT3-deficient MEFs, we transiently expressed WT STAT3 with a GFP-
empty vector or vectors encoding the HIES mutants, in different WT:mutant ratios, 
along with a STAT3 reporter plasmid containing 3 consecutive STAT3 consensus 
binding sites upstream of the firefly luciferase gene. After 48 hours, we stimulated the 
cells with IL-6 and sIL-6Rα and then assayed 3 hours later for luciferase activity using 
the Dual-luciferase reporter assay system, to measure STAT3 transcriptional activity 
(Fig. 13). WT STAT3 alone stimulated a 2-3 fold increase in STAT3 reporter activity in 
response to IL-6/sIL-6Rα, relative to the empty vector non-stimulated samples. The 
R382W mutant significantly reduced STAT3 reporter activity by 2-fold at a 4:1 ratio to  
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WT (p<.05), and approximately 3 fold at a 10:1 ratio (p<0.01). The V713L mutation, 
also showed a trend toward dominant negative activity at a 4:1 ratio to WT, and 
significantly reduced STAT3 reporter activity at a 10:1 ratio with WT (p<0.001). 
Surprisingly, the mutation located in the SH2 domain, which led to a complete lack of 
phosphorylation and lack of transcriptional activity, failed to significantly diminish 
STAT3 reporter activity, although there was a decrease of reporter activity at a 10:1 
ratio with WT (Fig. 13).  
 To further examine the dominant negative activity of these mutants in a less 
artificial setting, we examined the relative level of Socs3 mRNA after IL-6 stimulation in 
RAW cells stably expressing each of the HIES mutants. We stimulated these cells for 
30, 60, or 120 minutes and then assayed Socs3 mRNA expression by qPCR (Fig. 14). 
Socs3 expression peaked at 30 minutes in cells overexpressing WT STAT3, and 
stayed elevated even at 2 hours post-stimulation. When each HIES mutant was stably 
overexpressed, the Socs3 mRNA expression had similar expression kinetics, peaking 
at 30 minutes post-stimulation. However, Socs3 expression was significantly 
decreased in comparison to WT STAT3 (p<.001) at 60 minutes for the R382W and 
V637M mutants. The V713L mutant, on the other hand, never resulted in significantly 
lower Socs3 expression compared to WT STAT3. Additionally at 2 hours, the R382W 
mutant maintained significantly decreased Socs3 mRNA expression (p<.05) whereas 
the V637M mutant did not, although Socs3 expression was still low compared to WT. 
Together, these data suggest that the DNA-binding domain, SH2 domain, and TAD 
mutations impart a dominant negative ability upon STAT3, although differences appear 
to exist in their effects depending on the assay system used.  
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Effect of STAT3 function on osteoclast-specific gene expression 
 In addition to determining whether specific HIES mutations were inhibiting 
STAT3’s function via interfering with its phosphorylation or transcriptional ability, we 
sought to further examine how these mutations affected the function of STAT3 in 
phenotypes observed in both hematopoietic STAT3-deficient mice and patients with 
HIES.  
Upon exposure to RANKL, cells of the monocyte/macrophage lineage begin to 
differentiate into osteoclasts [103]. RANKL stimulation results in the activation of NFκB 
[104], and osteoclast differentiation is NFκB dependent [17]. As these cells further 
differentiate from the precursors to mature activated osteoclasts, they up-regulate 
expression of genes specific for their function, which include, but are not limited to 
Acp5/ACP5 (TRAP), Ctsk/CTSK (CSK), and Calcr/CALCR (CALC) (Fig 1b)[15][16].  
 We originally sought to investigate whether and how STAT3 regulates 
osteoclast differentiation using RAW cells, which have been shown to undergo 
RANKL-responsive osteoclast differentiation [105-108], however we had difficulties 
inducing sufficient differentiation of these cells. Therefore, we obtained a small 
molecule STAT3 inhibitor from Dr. John McMurray at M. D. Anderson Cancer Center. 
This inhibitor functions as an antagonist for the SH2-domain of STAT3. By physically 
interacting with this domain, the inhibitor should not only prevent STAT3’s interaction 
with the phospho-tyrosine on the cytoplasmic domain of the STAT3-activating receptor 
thereby inhibiting its tyrosine phosphorylation, but also prevent dimerization and 
subsequent activation, very much similar to how we hypothesize the V637M mutation 
affects STAT3. To verify the effect of the inhibitor on STAT3 tyrosine phosphorylation, 
we isolated total bone marrow from C57BL/6J mice and stimulated cells with 
granulocyte-colony stimulating factor (G-CSF), a STAT3-activating cytokine, in the 
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presence of increasing concentrations of the STAT3 inhibitor. Since the inhibitor was 
dissolved in dimethylsulfoxide (DMSO), we used DMSO treatment for 30 minutes as a 
control. We examined cell lysates by immunoblotting for tyrosine phosphorylated 
STAT3, total STAT3, and α-tubulin, with that latter serving as a loading control (Fig. 
15a). These assays showed that as the concentration of the inhibitor increased, the 
amount of STAT3 tyrosine phosphorylation substantially decreased and eventually 
was undetectable. As expected, the inhibitor had no effect on the relative abundance 
of STAT3 protein, as the amount of total STAT3 remained the same.  
 Next, we cultured total murine bone marrow from C57BL/6J mice in the 
presence of conditioned medium containing macrophage-colony stimulating factor (M-
CSF) for 3 days to generate bone marrow-derived macrophages. The macrophages 
were subsequently cultured for 4 days in the presence of RANKL with varying 
concentrations of the STAT3 inhibitor. The gene expression of the three osteoclast-
specific genes was analyzed by quantitative real-time PCR (qPCR)(Fig. 16). We found 
that with increasing concentrations of inhibitor, and thus less activated STAT3, the 
expression of Acp5 (TRAP), Ctsk (CSK), Calcr (CALC) were all significantly up-
regulated. This indicates a role for the STAT3 SH2-domain, as well as activated 
STAT3, in the negative regulation of osteoclast differentiation and expression of genes 
important for osteoclast function.  
 
Analysis of the effect of the HIES mutations on inflammatory gene expression in 
mouse macrophages stimulated with LPS 
 NFκB activity is not only important for osteoclastogenesis, but is also highly 
involved in the inflammatory response [19][20][21]. To determine whether STAT3 is 
involved in another NFκB-mediated pathway, and whether the HIES point mutations  
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deregulate this pathway, we examined LPS-responsive gene expression. LPS is a 
known ligand for TLR4. Activation of TLR4 by LPS also induces the activation of NFκB 
[23][24][26]. Thus, we overexpressed the HIES mutant constructs in the mouse 
macrophage cell line, RAW, and examined LPS-responsive gene expression.  
 After confirmation of the expression of the STAT3 HIES mutants in RAW cells 
(Fig. 8), we stimulated the cells with LPS 0, 1, 2 or 6 hours and assayed the 
expression of inflammatory genes known as NFκB targets, including Il6, Tnf (TNFα), 
and Cxcl10 (IP-10) (Fig. 17). We found in cells overexpressing WT STAT3 that Il6 
expression peaked at 6 hours post-stimulation with an approximate 200-fold induction 
relative to unstimulated cells. Cxcl10 mRNA also peaked with similar kinetics with an 
approximate 15-fold increase in expression relative to unstimulated cells. Tnf mRNA 
expression appeared much earlier, at 1 hour, and remained at similar levels 
throughout the time-course. In addition, Tnf mRNA had the lowest fold induction of the 
three genes (2x increase) compared to unstimulated cells. RAW cells overexpressing 
the STAT3 V637M mutant showed significantly higher expression of Il6 at 6 hours both 
in relative expression (p<.001) and fold induction (p<.01) (Fig. 17, upper left and right 
panels, respectively), compared to cells expressing WT STAT3. This Il6 expression 
reached as high as a 400-fold increase relative to unstimulated cells, almost twice 
what WT STAT3 was found to induce. The V637M mutant displayed similar kinetics of 
IL6 expression to WT STAT3. Cells expressing this mutant displayed comparable 
mRNA expression levels and kinetics for Cxcl10 and Tnf, although the kinetics of Tnf 
expression were slightly different with the expression peaking at 2 hours versus WT 
which peaked at 1 hour. Cells expressing the V713L mutant displayed significantly 
higher IL-6 expression, similar to the V637M mutation, again reaching almost twice the 
induction of WT. However, statistical significance was not obtained with either Cxcl10  
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or Tnf mRNA expression. Interestingly, while overexpressing STAT3 with the R382W 
mutation resulted in slightly higher levels of all three genes, in no case was this 
significant. Thus the HIES mutations we investigated lead to enhanced NFκB-
mediated inflammatory gene expression in macrophages following TLR4 activation, 
which suggests that STAT3 function may be important for restraining this gene 
expression. 
 
Analysis of the LPS-induced inflammatory gene expression in mouse embryonic 
fibroblasts overexpressing STAT3 
 While it is evident that STAT3 negatively regulates NFκB-mediated 
inflammatory gene expression in macrophages, and that the domains thought to be 
important for transcriptional function participate in this regulation, we were interested in 
whether STAT3 also participates in a similar manner in non-hematopoietic tissues. 
This would establish STAT3 as a more global regulator of inflammatory gene 
expression. To evaluate this possibility, we used a STAT3-deficient MEF cell line and 
reconstituted with WT STAT3 or GFP-empty vector (Fig. 10) as a reference for gene 
expression in the absence of STAT3 and to control for the effect the infection may 
have had on this gene expression.   
 To examine the effect of STAT3 on NFκB-mediated inflammatory gene 
expression in fibroblasts, we stimulated the MEFs expressing either WT STAT3 or 
GFP-empty vector with LPS and then assayed expression of NFκB inflammatory gene 
targets via qPCR (Fig. 18). We found a markedly decreased expression of Il6, Cxcl10, 
and Il12 mRNA after WT STAT3 overexpression compared to the GFP-empty 
transduced STAT3-deficient cells. The relative expression levels of Il6 and Cxcl10 
became significantly less in WT cells than GFP-empty at 2 hours (p<.05) (Fig. 18a),  
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and a similar result was obtained when examining the fold change (Fig. 18b). Il6, 
Cxcl10 and Il12 were also significantly induced in GFP-empty transduced cells 
compared cells expressing WT STAT3 (Fig. 18b). When WT STAT3 was absent, Il6 
and Cxcl10 expression were induced 2 fold more than when STAT3 was present. Il12 
was induced up to 7 fold when similarly compared.  
Interestingly, the forced expression of STAT3 also changed the kinetics of the 
expression for both IL6 and IL12. IL6 mRNA expression peaked at 2 hours in cells 
expressing GFP-empty vector whereas the WT STAT3 overexpressing cells exhibited 
delayed induction peaking at 4 hours (Fig. 18a). Significantly, IL12 showed no 
induction when STAT3 was present and was 7 fold less than empty-vector transduced 
STAT3-deficient cells (Fig. 18b). Thus, in non-hematopoietic tissues, STAT3 functions 
similarly as in immune cells by inhibiting LPS-induced NFkB-mediated inflammatory 
gene expression. 
 
The effect of HIES mutants on LPS-induced inflammatory gene expression in 
STAT3-deficient MEFs 
 Our results showed that overexpression of STAT3 HIES mutants resulted in 
increased inflammatory gene expression in macrophages (Fig. 17), and that STAT3 
overexpression in STAT3-deficient MEFs dampened inflammatory gene expression 
(Figs. 18a & 18b), indicating STAT3 negatively regulates inflammatory gene 
expression in both systems. Thus, we sought to examine the affect of these mutants 
on inflammatory gene expression in STAT3-deficient MEFs. We stimulated MEFs that 
stably express the HIES mutants with LPS for 2 or 4 hours and assayed for Il6, 
Cxcl10, and Il12 mRNA expression by qPCR. Surprisingly, we found no increase in 
either Il6 or Cxcl10 expression at either time point (Fig. 19). We did observe increased  
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Il12 gene expression levels in cells expressing the HIES mutants compared to cells 
expressing WT STAT3, however they were determined to be statistically insignificant. 
Il6 showed significantly lower expression in cells with the V637M and V713L mutants 
in comparison to cells with WT STAT3. Cxcl10 showed significantly lower expression 
only in the V713L mutant cells. Thus, expressing the HIES mutants in MEFs lacking 
endogenous STAT3 does not enhance their expression of LPS-induced inflammatory 
gene compared to WT STAT3 as was initially hypothesized. 
 
Examination of mitogen activated protein kinase (MAPK) signaling after LPS 
stimulation in macrophages expressing the HIES mutants 
 Both the cytokine profile we observed with the HIES STAT3 point mutations in 
murine macrophages (Fig. 17), and the cytokines found in the blood of patients with 
HIES [84][89], indicate a possible role for involvement of both NFκB and MAPK 
signaling in hematopoietic cells. Il6 and Cxcl10 are regulated by both NFκB and AP-1 
binding in their promoters [109][110] and Tnf expression has also been linked to both 
NFκB and AP-1 activation [111]. In addition, in B-cells, NFκB regulates AP-1 activation 
after LPS stimulation [112]. Therefore, we hypothesized that the enhanced 
inflammatory gene expression in RAW cells could be due to the activation of both 
signaling pathways. 
 Using the RAW cells overexpressing either WT STAT3 or STAT3 HIES 
mutants, we stimulated them with LPS for 5, 15, or 30 minutes and then analyzed 
phosphorylation of c-Jun N-terminal Kinase 1 (JNK1) by immunoblot (Fig. 20). JNK1 is 
downstream of TAK1 but upstream of AP-1 in the MAPK pathway [113][114]. JNK1 
becomes activated after tyrosine phosphorylation [114]. In cells overexpressing WT 
STAT3, we found that JNK was activated by 30 minutes post-stimulation. Conversely,  
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when any of the HIES mutants were overexpressed, pJNK1 levels appeared as early 
as 5 minutes with significantly higher expression, compared to macrophages 
expressing WT STAT3, as stimulation time increased to 15 and 30 minutes.  
Our preliminary data examining whether the STAT3 HIES mutants affect NFκB 
activation, using analysis of phosphorylated-IκBα and degradation of IκBα, indicates a 
possible enhancement of NFκB activation as well but further confirmation is required 
(data not shown). Thus, our results suggest that loss of STAT3 function leads to 
enhanced MAPK signaling, which may be partially responsible for the increased 
inflammatory gene expression we observe in the macrophages expressing the HIES 
STAT3 mutants. Our preliminary results also indicate a possible increase in NFκB 
signaling in the presence of STAT3 HIES mutant overexpression. 
 
Discussion 
 
 STAT3 is an important molecule in many diverse and distinct cellular processes 
including survival, proliferation, differentiation, inflammation and oncogenesis 
[36][41][43][67}[76][77]. Traditionally STAT3 has been described as a transcription 
factor, similar to the other STAT family members [45]. New evidence suggests that this 
may be an oversimplified view of the ways STAT3 functions within a cell [61][62][63]. 
Previous studies have described an anti-inflammatory role for STAT3 through 
participation in and regulation of IL-10 signaling [69][70]. In this project, we examine 
another mechanism whereby STAT3 may negatively regulate inflammation and 
differentiation, via crosstalk with the NFκB signaling pathway. We sought to better 
understand how this regulation occurs, and to gain more insight into how the mutations 
in HIES lead to enhanced inflammatory gene expression.  
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 Previous studies have identified various mutations in the STAT3 gene in 
humans diagnosed with Hyper-IgE syndrome [88][89]. The majority of these are point 
mutations with several deletions also identified. Interestingly, all of these mutations 
were found in domains thought to be important for STAT3 transcriptional activity 
[53][54]. To examine how the different domains affect STAT3’s regulation of NFκB-
mediated gene expression, we chose to analyze three of these point mutations, one in 
each different domain (DNA-binding, SH2, TAD) (Fig. 6).  
 To understand the mechanism by which these mutants were affecting the 
function of STAT3, we first had to analyze their activation potential. Previous studies 
have suggested that STAT3 containing a mutation in the DNA-binding domain 
(R382W) can be tyrosine phosphorylated whereas STAT3 containing a mutation found 
in the SH2 domain (V637M) cannot be [98]. These studies were conducted in COS-7 
cells, which express a low level of endogenous STAT3 [55], transiently transfected 
with either STAT3 mutant construct after EGF stimulation, therefore we wanted to 
confirm this observation in cells stably expressing the HIES mutants without any 
confounding endogenous STAT3.  
Using STAT3-deficient MEFs expressing the STAT3 HIES mutants, we 
confirmed the previous observation that the R382W mutant can be tyrosine 
phosphorylated [98] (Fig. 11). We also observed slightly higher amounts of tyrosine 
phosphorylation of the R382W mutant than that in WT STAT3 expressing cells despite 
similar total STAT3 levels (Fig. 11). We also observed this enhanced tyrosine 
phosphorylation when we examined total STAT3 activation in RAW cells expressing 
the STAT3 HIES mutants (Fig. 9a). This may indicate a mechanism that fails to 
attenuate the cytokine signal leading to prolonged phosphorylation. One explanation 
could be the lack of SOCS3 (Fig. 14) due to the loss of the R382W mutant’s 
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transcriptional activity (Fig. 12). SOCS3 has been shown to be an important inhibitor of 
cytokine signaling, especially after IL-6 stimulation in vivo [72]. We also confirmed the 
previous observation that the V637M mutation completely prevents STAT3 from 
becoming tyrosine phosphorylated [98]. We hypothesize the mutation may somehow 
prevent STAT3 binding the phosphotyrosine on gp130, similarly to how the STAT3 
inhibitor leads to diminished STAT3 tyrosine phosphorylation after G-CSF stimulation 
(Fig. 15a). However, further analysis is required to confirm that this mutation physically 
prevents STAT3’s association with the phosphotyrosine on gp130 or by some other 
unknown mechanism. Since the identification of the mutation in the TAD (V713L) has 
been established [98], no research has been focused on determining how this 
mutation alters STAT3 function to result in the HIES phenotype. To our knowledge we 
are the first to show that the V713L mutation does not completely block STAT3’s ability 
to become tyrosine phosphorylated (Fig. 11). However, STAT3 containing this 
mutation becomes phosphorylated less efficiently than either WT STAT3 or STAT3 
with the R382W mutation. Interestingly, and in accordance with this modest 
phosphorylation, we also showed this mutant has a low level of transcriptional ability 
(Fig. 12), which would make it difficult to ascribe dominant negative ability to this 
mutant, at least in terms of severely blocking WT STAT3’s transcriptional function.   
In order for a protein to be considered dominant negative, it must interfere with 
the function of the WT protein often exhibiting a phenotype more severe than the loss 
of only a single allele [115]. To determine whether each of the STAT3 HIES mutants 
was dominant negative, we overexpressed these mutants in a murine macrophage cell 
line (RAW), which expresses endogenous STAT3 (Fig. 9b). We sought to examine 
whether these mutants affected total STAT3 phosphorylation in the presence of 
endogenous STAT3. We again observed an enhanced tyrosine phosphorylation with 
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the R382W mutant and moderately less tyrosine phosphorylated STAT3 in the V713L 
expressing cells (Fig. 9a). The data from the STAT3-deficient MEFs after IL-6 
stimulation indicates the V637M mutant has a complete defect in tyrosine 
phosphorylation (Fig. 11). Therefore, we conclude that the phosphorylated STAT3 
observed in the RAW cells expressing the V637M STAT3 mutant (Fig. 9a) is solely the 
endogenous STAT3. Additionally, this phosphorylation level is similar to the level 
found in uninfected RAW cells (Fig. 9b). Unfortunately, due to the intrinsic tyrosine 
phosphorylation of the R382W and V713L mutants, it was difficult to conclude whether 
they abrogated phosphorylation of endogenous STAT3. We may be able to infer their 
effect, however, based on what we know about the location of each mutation. The 
R382W mutation is located in the DNA-binding domain and has no effect on the 
intrinsic tyrosine phosphorylation of STAT3; therefore we could hypothesize that this 
mutant would have no inhibitory effect on phosphorylation of endogenous STAT3. The 
V637M mutation is in the SH2 domain and therefore completely prevents tyrosine 
phosphorylation of STAT3, presumably due to a defect in the interaction at the 
receptor. This also should not affect endogenous STAT3 phosphorylation because the 
phosphorylation occurs with the monomeric STAT3. For the same reason, we can 
hypothesize the V713L mutant would not affect endogenous STAT3 phosphorylation. 
So the question remained, if these mutations are not affecting the phosphorylation of 
WT STAT3, do they truly exert dominant negative activity and if so, how is this 
accomplished? 
The initial paper describing the STAT3 mutations within the DNA-binding 
domain in patients with HIES tested the dominant negative activity of the R382W 
mutant through analysis of its effect on the ability of WT STAT3 to initiate transcription 
of a STAT3 reporter [88]. In this study, Minegishi et al analyzed the dominant negative 
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activity in cells expressing a low level of endogenous STAT3 [116] and did not report 
the ratio of WT STAT3 to mutant STAT3 required for inhibition. Therefore, we sought 
not only to confirm the dominant negative activity of the R382W mutant and determine 
the potency by which it accomplishes this activity, but also examine the dominant 
negative activity of the V637M and V713L mutants. We chose to use the STAT3-
deficient MEF cell line to eliminate the confounding effect of endogenous STAT3 and 
more accurately determine the amount of mutant protein needed to inhibit WT STAT3 
activity. As expected, we found that the R382W STAT3 mutant inhibited WT STAT3’s 
ability to initiate transcription of a STAT3 luciferase reporter; however this inhibition 
required four times as much mutant protein to obtain statistical significance (Fig. 13). 
The V637M mutant, which failed to be phosphorylated and most likely failed to 
inhibit phosphorylation of endogenous STAT3, also failed to inhibit WT STAT3’s 
transcriptional function as judged by the reporter assay. In contrast, macrophages 
stably expressing this mutant exhibited significantly reduced Socs3 gene expression 
(Fig. 14). This is indicative of the V637M mutant protein interfering with endogenous 
WT STAT3 function [101][102]. The disagreement between these two sets of data 
could be a technical issue given the amount of mutant needed to elicit any inhibition in 
the luciferase assays (4:1 at the least), or it could indicate that the reduction in Socs3 
gene expression is a due to a mechanism independent of directly blocking 
transcription. Interestingly, the V713L mutation exhibits a trend toward dominant 
negative activity over WT STAT3’s transcriptional function (Fig. 13) as low as a 4:1 WT 
to mutant ratio with significance arising at 1:10. However, while the level of Socs3 is 
diminished compared to WT, the change is insignificant and nowhere near the level 
observed with the R382W and V637M mutants (Fig. 14). This may be due in part to 
the inherent transcriptional ability of this mutant on its own (Fig. 12).  
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 The only mutation for which any direct mechanism has been elucidated is the 
R382W mutation, which was shown to completely abrogate the DNA-binding ability of 
STAT3 to the Socs3 promoter [117]. Our Socs3 gene expression results in both 
macrophages and MEFs, and our reporter assay results with this mutation, correlate 
well with this data. On the other hand, no evidence has been provided regarding the 
mechanism by which the other two mutants, V637M and V713L, functionally inhibit 
STAT3 activity. Our data confirm the total lack of phosphorylation of the V637M mutant 
[98] but show that it most likely does not affect endogenous WT STAT3 
phosphorylation or direct transcriptional function. However this mutant still interferes 
with WT STAT3’s function as shown through the reduced Socs3 expression in RAW 
cells expressing this mutant. Initially, we hypothesized that in the HIES patient setting, 
the reduction in WT STAT3 activity in the presence of the V637M mutant allele could 
be due to an overall reduction in available WT STAT3 within the cell. This is due to the 
fact that ideally at a 1:1 WT to mutant ratio, the presence of this mutant would reduce 
the amount of transcriptionally active WT STAT3 by 50%. Due to the importance of 
STAT3 in many cellular processes [36][42][43][52] and the conclusion that this 
mutation is responsible for the HIES phenotype in several individuals [89], this 
hypothesis seems plausible. However, given that mice lacking one full WT STAT3 
allele show no adverse affects and do not present with an HIES phenotype [52], this 
may not be the explanation. However it is possible this mutation does block the ability 
of WT STAT3 to initiate transcription but due to technical difficulties or the sensitivity of 
our luciferase assay we were unable to detect it. To confirm this hypothesis would 
require further study.  
 As we showed, the V713L mutation doesn’t fully inhibit phosphorylation of 
STAT3, thus it has a minimal amount of transcriptional activity. Even so, it significantly 
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reduced WT STAT3’s ability to transcribe the luciferase gene in our reporter assays 
and marginally reduced SOCS3 expression in RAW cells. We believe this lends 
evidence to our hypothesis that this mutation, by participating in the formation of the 
SH2 domain, may lead to unstable interactions either at the receptor or once 
dimerized. This could lead to attenuated dimerization once phosphorylated or once 
bound to promoters. Further elucidation of this mechanism would require either co-
immunoprecipitations with the receptor or in vitro binding assays. It is also possible 
that this mutation changes the conformation of the TAD such that it is no longer able to 
enhance transcription [55].  
 Now that we have a little better idea of how these mutants function, we sought 
to utilize them to determine how STAT3 may be interacting with the NFκB signaling 
pathway resulting in the phenotypes observed in patients with HIES and mice lacking 
hematopoietic STAT3 (Table 1). We chose to focus primarily on the increased 
osteoporosis and inflammation. The cytokine profile we examined was based on 
previous reports regarding known NFκB and AP-1 targets, namely Il6, Cxcl10 (IP-10), 
Tnf (TNFα), and Il12 [78][109][110][111][118][119]. As figures 1 and 2 depict, the 
RANKL and LPS pathways share several common elements upstream of the most 
striking similarity, NFκB activation. Both pathways use TRAF6 at early stages to lead 
to the activation of TAK1 [8][22][120]. TAK1 is a common signaling component 
between the NFκB and MAPK pathways. This corroborates the data showing that the 
majority of the inflammatory cytokines enhanced in HIES are targets of the terminal 
transcription factors of these two pathways (NFκB and AP-1) [114-116]. Due to the 
deregulation of both of these pathways in patients with HIES and mice lacking STAT3 
in the hematopoietic system [66][67][84][89][121](Table1), we hypothesized that 
STAT3 might act to negatively regulates both pathways through a common signaling 
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component, however confirming this was out of the scope of the current project. We 
chose to focus on whether STAT3 was negatively regulating these pathways via a 
transcriptional mechanism or an alternative method.  
 Our data indicated an importance for the SH2 domain in regulating 
osteoclastogenesis through the use of an antagonistic inhibitor for this domain (Fig. 
16). Due to difficulties in differentiating the RAW cells, in addition to technical issues 
infecting primary murine macrophages, we were unable to verify the involvement of 
the other domains using the STAT3 HIES mutants. However, we can establish a 
tenuous indirect importance of the DNA-binding and SH2 domains due to the presence 
of osteoclastogenesis deregulation in patients carrying mutations in these domains 
[89][98]. 
 With regards to the enhanced inflammatory gene expression seen in both 
human patients and hematopoietic STAT3-deficient mice, we have clearly indicated a 
function for the DNA-binding domain, SH2 domain, and TAD in this regulation. In all 
three cases, we saw increased mRNA expression of Il6, Cxcl10, Tnf compared to WT 
STAT3. Even in non-hematopoietic tissues, such as MEFs, we have shown that 
STAT3 expression significantly reduced the mRNA expression of Il6, Cxcl10, Il12 (Fig. 
18). However, in non-hematopoietic cells, the HIES mutants may not be acting as they 
do in the macrophages because we see a significant reduction in expression of these 
genes after LPS stimulation (Fig. 19) which is in stark contrast to our data comparing 
GFP-empty vector transduced cells with WT STAT3 transduced cells (Fig. 18). This 
may indicate that MEFs are not a good system for our analysis or, more likely that the 
mechanism we hypothesize that is leading to increase inflammatory gene expression, 
is not active in non-hematopoietic cells.   
	   84	  
 Next we wanted to further examine the developing relationship between STAT3 
and NFκB. To this point, we had only shown indirectly that loss of STAT3 function, by 
mutation or exogenous inhibition of the DNA-binding domain, SH2 domain, or TAD 
leads to increased gene expression of inflammatory mediators, which are NFκB and 
AP-1 targets, and enhanced osteoclastogenesis, a process that is NFκB-dependent. 
Therefore, we intended to examine whether the loss of STAT3 function led to 
increased NFκB activation. Preliminary results examining phosphorylation of the 
inhibitor of NFκB, IκBα, showed enhanced phosphorylation as well as enhanced 
degradation (data not shown), which follows this phosphorylation [122]. We examined 
the phosphorylation of JNK1, which is part of the MAPK pathway downstream of TAK1 
activation and serves to activate the AP-1 family of transcription factors [113][114]. 
Cells expressing the HIES mutants began activating JNK1 as early as 5 minutes post-
stimulation (Fig. 20), which was significant because cells expressing WT STAT3 did 
not exhibit JNK phosphorylation until 30 minutes post-LPS stimulation. This suggests 
that MAPK signaling, induced by TLR4 activation of macrophages, is negatively 
regulated by STAT3 and most likely deregulated in patients with HIES. 
  In this study, we have shown that STAT3 negatively regulates NFκB and 
MAPK-mediated inflammatory gene expression in both macrophages and non-
hematopoietic fibroblasts. In addition, we found that STAT3 inhibits the expression of 
genes specific for osteoclastogenesis, a process that is NFκB dependent. We have 
shown that the SH2 domain is required for this regulation and that the DNA binding 
domain and the TAD are also involved in regulating the inflammatory gene expression. 
From our analysis of the point mutations identified in patients with HIES, we have 
confirmed previous reports regarding the activation capabilities of STAT3 when 
mutations occur in the DNA-binding and SH2 domains and we were the first to show 
	   85	  
that the V713L mutation doesn’t completely block STAT3 phosphorylation or 
transcriptional function. We demonstrated that the R382W, V637M, and V713L 
mutants elicit dominant negative activity either through reduction of luciferase reporter 
transcription or endogenous Socs3 expression. Data regarding the V637M mutant 
disagreed, raising several questions regarding how this mutation leads to the 
inflammatory and bone phenotypes observed in HIES. We have developed several 
alternative hypotheses, which will allow us to pursue answers to these questions in 
future studies.  
In one model, the V637M mutation could reduce the amount of global STAT3 
signals within the cell, which would be significant, as it would show what even a slight 
loss in STAT3 signaling could lead to. However in light of data in mice heterozygous 
for Stat3 [52], this seems unlikely. Another possibility came out of the evidence that 
this mutant STAT3 protein cannot be phosphorylated. Several groups have identified 
roles for unphosphorylated STAT3 (U-STAT3), which could offer alternative 
explanations for the observations obtained in this study regarding the V637M mutation. 
U-STAT3 has been shown to bind NFκB after IL-6 stimulation and lead to its activation 
by displacement of IκBα [68]. Another group identified a role for the Drosophila 
melanogaster STAT protein in maintaining heterochromatin stability [61] while a role 
was also identified for STAT4 and STAT6 in epigenetic modifications [64]. These 
observations could indicate that it is possible unphosphorylated STAT3 could regulate 
heterochromatin in such a way that it remains closed to the transcription of NFκB-
inhibiting proteins. However, we have to be careful to not overanalyze our data as this 
mutation could also function only to block binding and activation at the receptor but not 
to activated STAT3 monomers, something that has not been investigated. 
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 Our data indicates a role for STAT3 in regulating NFκB and MAPK signaling via 
its intrinsic transcriptional activity, and highlights the necessity for two fully functional 
STAT3 alleles. However there are gaps that need to be filled prior to drawing any 
further, definitive conclusions. To extend this work, we intend to determine what 
STAT3’s transcriptional target is and which protein in the NFκB pathway it is acting to 
repress. Secondly, we would like to determine the mechanism by which the V637M 
mutation is affecting STAT3’s regulation of NFκB signaling. Since STAT3 monomers 
carrying this mutation cannot be phosphorylated, presumably they cannot bind 
phosphorylated STAT3 monomers. This indicates that only WT STAT3 monomers 
would be involved in the signaling. Thus the defect seen in our system as well as 
patients with this mutation remains to be determined, but could either be due to the 
reduction in activatable STAT3 or an unknown mechanism for unphosphorylated 
STAT3. Finally, we intend to confirm whether the V713L mutation destabilizes STAT3. 
Does the instability affect binding at the receptor, the promoter, or somewhere in 
between? Could it be due to some other reason, such as a conformational changes 
shielding the tyrosine residue from the receptor associated JAKs or phosphorylation of 
the serine residue located with this domain? 
 Regardless of the several questions which this study raises, we have extended 
knowledge of the mechanism leading to enhanced inflammation and osteoporosis in 
patients with HIES. We have also established STAT3 as a negative regulator of NFκB- 
and MAPK- induced inflammatory gene expression and MAPK activation. 
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